Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC). According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation. The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.01.019 | DOI Listing |
Publication Analysis
Top Keywords
jak inhibitors
12
tofacitinib pregnancy
4
pregnancy assessing
4
assessing pregnancy
4
pregnancy infant
4
infant outcomes
4
outcomes cord
4
cord blood
4
blood breast
4
breast milk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!